{
    "organizations": [],
    "uuid": "a2137444ed7aed5d6ae2d6d36b8bd588975f25ad",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-macrogenics-posts-qtrly-net-loss-p/brief-macrogenics-posts-qtrly-net-loss-per-common-share-of-1-34-idUSASC0A05F",
    "ord_in_thread": 0,
    "title": "MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) - MacroGenics Inc:\n* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND 1ST QUARTER 2018 FINANCIAL RESULTS\n* MACROGENICS - IN H2, SEES TO PROVIDE CLINICAL UPDATES ON FLOTETUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AML, ON COMBINATION OF ENOBLITUZUMAB WITH ANTI-PD-1 AGENT\n* ANTICIPATE TWO OF CO’S ONCOLOGY PRODUCT CANDIDATES WILL MOVE INTO CLINICAL PIPELINE THIS YEAR\n* TOTAL REVENUE WAS $4.7 MILLION FOR QUARTER ENDED MARCH 31, 2018, COMPARED TO $2.1 MILLION\n* QTRLY NET LOSS PER COMMON SHARE $1.34 * Q1 EARNINGS PER SHARE VIEW $-1.08, REVENUE VIEW $6.8 MILLION — THOMSON REUTERS I/B/E/S Source text for Eikon:\nOur ",
    "published": "2018-05-08T04:44:00.000+03:00",
    "crawled": "2018-05-08T16:43:32.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "macrogenics",
        "inc",
        "macrogenics",
        "provides",
        "update",
        "corporate",
        "progress",
        "1st",
        "quarter",
        "financial",
        "result",
        "macrogenics",
        "h2",
        "see",
        "provide",
        "clinical",
        "update",
        "flotetuzumab",
        "patient",
        "aml",
        "combination",
        "enoblituzumab",
        "agent",
        "anticipate",
        "two",
        "co",
        "oncology",
        "product",
        "candidate",
        "move",
        "clinical",
        "pipeline",
        "year",
        "total",
        "revenue",
        "million",
        "quarter",
        "ended",
        "march",
        "compared",
        "million",
        "qtrly",
        "net",
        "loss",
        "per",
        "common",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon"
    ]
}